University of California San Francisco

Aras N. Mattis, MD, PhD

Mattis 144.jpg
Aras N. Mattis, MD, PhD

Assistant Professor, UCSF Department of Pathology

Address

513 Parnassus Avenue HSW
San Francisco, CA 94143
United States

Email: [email protected]

Biography

Aras N. Mattis, M.D., Ph.D., is a board-certified anatomic pathologist and clinical fellow in the Willenbring Lab. Dr. Mattis trained at the University of Illinois at Urbana-Champaign, earning both his doctorates, Biochemistry and Medicine, there in 2007. He continued his clinical training in Pathology at the University of California San Francisco completing residency in Anatomic Pathology with subsequent fellowship training in Surgical Pathology and Liver and gastrointestinal pathology under his clinical mentor, Dr. Linda Ferrell. Since 2010, he has worked in the Willenbring Lab, investigating the basic mechanisms of liver development and disease in the with a specific focus on liver metabolism and fatty liver disease as well as micro-RNA regulation of liver metabolism.

Education

Institution Degree Dept or School End Date
University of Illinois Urbana-Champaign PhD Biochemistry 2007
University of Illinois Urbana-Champaign MD Medicine 2007
University of California Berkeley BA Molecular and Cell Biology - Genetics 1998

Board Certifications

American Board of Pathology, Anatomic Pathology

Collaboration Interests

I am interested in:

  • academic collaboration
  • academic senate committee service
  • multicenter clinical research
  • companies and entrepreneurs
  • press

Clinical Expertise

Liver and Gastrointestinal Pathology

Program Affiliations

UCSF Department of Pathology

California Institute for Regenerative Medicine

Grants and Funding

  • Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIDDK | 2023-06-01 - 2028-05-30 | Role: MPI
  • Establishing patient-derived iPSCs as a platform for discovery research in NAFLD | NIH | 2023-06-01 - 2028-03-31 | Role: Co-Principal Investigator
  • Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH/NIDDK | 2024-02-01 - 2027-11-30 | Role: PI
  • Modeling and Characterization of NAFLD Phenotypes in a Severely Affected Family | NIH | 2024-02-01 - 2027-11-30 | Role: Principal Investigator
  • Genetic Regulation of Nonalcoholic Fatty Liver Disease | NIH | 2021-06-08 - 2025-03-31 | Role: MPI
  • Regulation of Lipid Metabolism by miR-29a within Hepatocytes | NIH | 2013-09-01 - 2019-07-31 | Role: Principal Investigator

Research Narrative

Dr. Mattis' postdoctoral work includes the use of translational human biopsy material as well as patient-derived induced pluripotent stem cell reprogramming to hepatocytes. As a long-term goal, this work aims to develop a humanized liver mouse model of fatty liver disease. Aras is supported by the UCSF CIRM clinical fellow training grant and continues to work closely with the UCSF Department of Pathology as a clinical researcher.

Research Interests

Liver diseases including metabolic, pediatric, fibrotic, idiopathic, stem cell derived

Hepatocytes for transplant and disease modeling, micro-RNA regulation of hepatocyte

Development and metabolism, liver and gastrointestinal tumors, site-specific recombination.

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Type 2 lymphocytes restrict type 3 lymphocytes during liver fibrosis and colocalize in fibroblast niches.
    Sbierski-Kind J, Cautivo KM, Nilsson J, Wagner JC, Dahlgren MW, Crystal NE, McClave M, Mroz NM, Ganslmeier M, Lizama CO, Gan AL, Matatia PR, Taruselli MT, Chang AA, Caryotakis S, O'Leary CE, Kotas M, Lee JH, Gu T, Seo H, Kim HJ, Mattis AN, Peng T, Locksley RM, Molofsky AB| | PubMed
  2. Loss of TMEM55B modulates lipid metabolism through dysregulated lipophagy and mitochondrial function.
    Qin Y, Teker SS, La Cunza N, Tong Y, Theusch E, Yang NV, Venkatesan L, Su J, Wang X, Krauss RM, Lakkaraju A, Mattis AN, Medina MW| | PubMed
  3. Predicting metabolic dysfunction-associated steatotic liver disease risk using patient-derived induced pluripotent stem cells.
    Qin Y, Chhetri P, Theusch E, Lim G, Teker SS, Kuang YL, Aziziraftar SK, Mehraban MH, Munoz-Howell A, Saxena V, Le Guillou D, Mattis AN, Maher JJ, Medina MW| | PubMed
  4. Modeling Familial MASH by iPSC-Hepatocytes.
    Esteva-Font C, Maher JJ, Rulifson E, Pabst M, Bass N, Willenbring H, Mattis AN| | PubMed
  5. Resolving fibrosis by stimulating HSC-dependent extracellular matrix degradation.
    Sharma S, Prathigudupu V, Cable C, Serrano LR, Nerella S, Chen A, Hassan G, Lakins J, Valenzuela CL, Tsukui T, Ramamoorthi R, Kim JJ, Willenbring H, Mattis AN, Volk RF, Zaro BW, Coon JJ, Beresis R, DeGrado WF, Weaver VM, Christenson SA, Jo H, Chen JY| | PubMed
  6. MIR192 Upregulates GLP-1 Receptor and Improves Statin-Induced Impairment of Insulin Secretion.
    Kuang YL, Locatelli CAA, Qin Y, Zhang Y, Theusch E, Muñoz-Howell A, Sanchez G, Lu M, Nguyen MA, Yalamanchili T, Wang X, Nalula G, Mattis AN, Oni-Orisan A, Iribarren C, Krauss RM, Mulvihill EE, Medina MW| | PubMed
  7. AAV capsid prioritization in normal and steatotic human livers maintained by machine perfusion.
    Kim JJ, Kurial SNT, Choksi PK, Nunez M, Lunow-Luke T, Bartel J, Driscoll J, Her CL, Dhillon S, Yue W, Murti A, Mao T, Ramos JN, Tiyaboonchai A, Grompe M, Mattis AN, Syed SM, Wang BM, Maher JJ, Roll GR, Willenbring H| | PubMed
  8. Predicting Metabolic Dysfunction Associated Steatotic Liver Disease Risk Using Patient-Derived Induced Pluripotent Stem Cells.
    Qin Y, Chhetri P, Theusch E, Lim G, Teker S, Kuang YL, Aziziraftar SK, Mehraban MH, Munoz-Howell A, Saxena V, Le Guillou D, Mattis AN, Maher JJ, Medina MW| | PubMed
  9. Fluoride-related changes in the fetal cord blood proteome; a pilot study.
    Tuomivaara ST, Fisher SJ, Hall SC, Goin DE, Mattis AN, Den Besten PK| | PubMed
  10. Human Hepatocytes Can Give Rise to Intrahepatic Cholangiocarcinomas.
    Hsu BY, Driscoll J, Human Cholangiocarcinogenesis Project, Tateno C, Mattis AN, Kelley RK, Willenbring H| | PubMed